NCT05926882

Efficacy of Oral Apremilast in the Treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Jinnah Postgraduate Medical Centre · Other Government
• Sex: All
• Age: 20 Years – 70 Years
• Healthy volunteers: Accepted

Summary

Alopecia areata (AA) is a disease characterized by hair cycle dysfunction and the presence of peribulbar and perifollicular mononuclear cell infiltrate.1 The majority of patients report the rapid onset of one or several well-defined, usually round, 1 to 4 cm areas of scalp hair loss. A common feature is the presence of "exclamation-mark" hairs that are broken and short hairs that taper proximally. Commonly used treatment modalities are steroids (intra-lesional, topical or systemic), contact immunotherapy, anthraline, minoxidil, calcineurine inhibitors, topical retinoids, systemic immune modulating agents, photo-chemotherapy, dermatography wigs and hypnotherapy etc Apremilast is a newer drug. It is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), this may be effective treatment for a variety of inflammatory skin disorders such as alopecia areata.

Detailed description

Due to its increasing prevalence and lack of local data on its long term management, the investigators designed current study On Efficacy of Oral Apremilast in Alopecia areata in-order to evaluate its effectiveness.

Conditions

• Alopecia Areata

Interventions

Type	Name	Description
DRUG	Apremilast 30mg	Patients will be given Oral Apremilast 30 mg twice daily after 05 days titration dose.

Timeline

• Start date: 2022-08-01
• Primary completion: 2023-06-20
• Completion: 2023-06-20
• First posted: 2023-07-03
• Last updated: 2023-07-03

Locations

1 site across 1 country: Pakistan